![](https://news.europawire.eu/wp-content/uploads/2013/12/novartis.jpg)
Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at a major medical meeting; worldwide regulatory filings are planned for 2015 Afinitor is already … Read the full press release